Evidence mapPaperPMID 31240636Full record

ReviewPharmacoEconomics2019

Transparency in Decision Modelling: What, Why, Who and How?

Christopher James Sampson, Renée Arnold, Stirling Bryan, Philip Clarke, Sean Ekins, Anthony Hatswell, Neil Hawkins, Sue Langham, Deborah Marshall, Mohsen Sadatsafavi and 3 more

Abstract readReview
In one paragraph

Review in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020
    Article
  13. Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christopher James SampsonOffice of Health Economics, 7th Floor, Southside, 105 Victoria Street, London, SW1E 6QT, UK. csampson@ohe.org.ORCID 0000-0001-9470-2369
Renée ArnoldArnold Consultancy & Technology, LLC, 15 West 72nd Street-23rd Floor, New York, NY, 10023-3458, USA.ORCID 0000-0001-5935-3220
Stirling BryanUniversity of British Columbia, 701-828 West 10th Avenue, Research Pavilion, Vancouver, BC, V5Z 1M9, Canada.ORCID 0000-0001-7093-3058
Philip ClarkeUniversity of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK.ORCID 0000-0002-7555-5348
Sean EkinsCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC, 27606, USA.ORCID 0000-0002-5691-5790
Anthony HatswellDelta Hat, 212 Tamworth Road, Nottingham, NG10 3GS, UK.ORCID 0000-0003-1129-326X
Neil HawkinsUniversity of Glasgow, Lilybank Gardens 1, Glasgow, G12 8RZ, UK.ORCID 0000-0003-3199-221X
Sue LanghamMaverex Limited, 5 Brooklands Place, Brooklands Road, Sale, Cheshire, M33 3SD, UK.ORCID 0000-0003-2088-3333
Deborah MarshallUniversity of Calgary, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada.ORCID 0000-0002-8467-8008
Mohsen SadatsafaviUniversity of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T1Z3, Canada.ORCID 0000-0002-0419-7862
Will SullivanBresMed Health Solutions, Steel City House, West Street, Sheffield, S1 2GQ, UK.ORCID 0000-0001-5221-7074
Edward C F WilsonHealth Economics Group, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK.ORCID 0000-0002-8369-1577
Tim WrightsonAdis International Limited, 5 The Warehouse Way, Northcote, 0627, Auckland, New Zealand.

Funding

NIGMS NIH HHS R43 GM122196NIGMS NIH HHS R44 GM122196
6 · The paper itself

Abstract

Transparency in decision modelling is an evolving concept. Recently, discussion has moved from reporting standards to open-source implementation of decision analytic models. However, in the debate about the supposed advantages and disadvantages of greater transparency, there is a lack of definition. The purpose of this article is not to present a case for or against transparency, but rather to provide a more nuanced understanding of what transparency means in the context of decision modelling and how it could be addressed. To this end, we review and summarise the discourse to date, drawing on our collective experience. We outline a taxonomy of the different manifestations of transparency, including reporting standards, reference models, collaboration, model registration, peer review and open-source modelling. Further, we map out the role and incentives for the various stakeholders, including industry, research organisations, publishers and decision makers. We outline the anticipated advantages and disadvantages of greater transparency with respect to each manifestation, as well as the perceived barriers and facilitators to greater transparency. These are considered with respect to the different stakeholders and with reference to issues including intellectual property, legality, standards, quality assurance, code integrity, health technology assessment processes, incentives, funding, software, access and deployment options, data protection and stakeholder engagement. For each manifestation of transparency, we discuss the 'what', 'why', 'who' and 'how'. Specifically, their meaning, why the community might (or might not) wish to embrace them, whose engagement as stakeholders is required and how relevant objectives might be realised. We identify current initiatives aimed to improve transparency to exemplify efforts in current practice and for the future.

Indexed as

Decision MakingDecision Support TechniquesHumansIntellectual PropertySoftwareTechnology Assessment, Biomedical

Identifiers

PMID31240636
PMCPMC8237575

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.